Lasofoxifene: Difference between revisions
m Protected "Lasofoxifene": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)) |
m Robot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +) |
||
| Line 1: | Line 1: | ||
| Line 36: | Line 36: | ||
{{Sex hormones}} | {{Sex hormones}} | ||
[[Category:Tartrates]] | [[Category:Tartrates]] | ||
[[Category:Selective estrogen receptor modulators]] | [[Category:Selective estrogen receptor modulators]] | ||
Revision as of 16:47, 9 August 2012
 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C28H31NO2 |
| Molar mass | 413.55 or 563.64 (with tartrate) |
|
WikiDoc Resources for Lasofoxifene |
|
Articles |
|---|
|
Most recent articles on Lasofoxifene Most cited articles on Lasofoxifene |
|
Media |
|
Powerpoint slides on Lasofoxifene |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Lasofoxifene at Clinical Trials.gov Clinical Trials on Lasofoxifene at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Lasofoxifene
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Lasofoxifene Discussion groups on Lasofoxifene Patient Handouts on Lasofoxifene Directions to Hospitals Treating Lasofoxifene Risk calculators and risk factors for Lasofoxifene
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Lasofoxifene |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Lasofoxifene (INN) (proposed tradename Fablyn) is a selective estrogen receptor modulator (SERM) which is under development for the prevention and treatment of osteoporosis and for the treatment of vaginal atrophy.
In September 2005, Pfizer Inc. received a non-approvable letter from the U.S. Food and Drug Administration regarding lasofoxifene (Oporia®), a selective estrogen receptor modulator for the prevention of osteoporosis.
On January 2008, Ligand Pharmaceuticals, through its marketing partner, Pfizer, submitted a New Drug Application for lasofoxifene, which is now to be marketed under the tradename Fablyn.
References
External links
- Pages with script errors
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Tartrates
- Selective estrogen receptor modulators
- Endocrinology